摘要
目的 探讨肺力咳合剂联合西药治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床效果。方法 选择2021年1月至2022年8月宜春市中医院收治的AECOPD患者60例,随机分为两组。对照组30例采用西药治疗,观察组30例加用肺力咳合剂治疗。比较两组症状改善时间、血清学指标、改良版英国医学研究委员会呼吸问卷(m MRC)评分、自我评估测试问卷(CAT)评分及运动耐量、生活质量,并观察药物安全性。结果 观察组喘息消失时间为(3.66±0.96)d、咳痰缓解时间为(4.07±1.22)d、咳嗽缓解时间为(4.39±1.43)d、哮鸣音缓解时间为(6.11±1.39)d,均短于对照组的(5.17±1.55)d、(6.58±1.49)d、(7.04±1.86)d、(7.67±2.84)d,差异有统计学意义(P<0.05)。观察组治疗后血清学指标低于对照组,差异有统计学意义(P<0.05)。观察组治疗后m MRC评分为(1.14±0.37)分、CAT评分为(10.39±2.31)分,均低于对照组的(2.54±0.58)分、(17.65±3.48)分,6 min步行试验(6MWT)为(311.71±48.50)m、健康调查简表(SF-36)评分为(78.34±9.35)分,高于对照组的(279.34±44.72)m(、71.15±12.24)分,差异有统计学意义(P<0.05)。两组药物安全性均理想,未见明显不良反应。结论 AECOPD患者采用肺力咳合剂联合西药治疗利于促进患者转归,加快症状缓解,使气道炎症反应明显减轻,改善运动耐量及生活质量,值得临床广泛应用。
Objective To investigate the clinical effect of feilike mixture combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods 90 patients with AECOPD admitted to Yichun Hospital of Traditional Chinese Medicine from January 2021 to August 2022 were selected and randomly divided into 2 groups.30 cases in the control group were treated with western medicine,based on this,30 cases in the observation group were additionally treated with feilike mixture.The two groups'symptom improvement time,serological indexes,modified British Medical Research Council Respiratory Questionnaire(mMRC)scores,self-assessment questionnaire(CAT)scores and exercise tolerance and quality of life were compared,and the safety of the drug was observed.Results In the observation group,the time of wheezing disappearance was(3.66±0.96)d,the time of sputum relief was(4.07±1.22)d,the time of cough relief was(4.39±1.43)d,and the time of wheezing relief was(6.11±1.39)d,shorter than those of the control group(5.17±1.55)d,(6.58±1.49)d,(7.04±1.86)d,(7.67±2.84)d,the differences were statistically significant(P<0.05).The serological indexes of the observation group after treatment were lower than those of the control group,and the difference was statistically significant(P<0.05).After treatment,the mMRC and CAT scores of the observation group were(1.14±0.37)points and(10.39±2.31)points,which were lower than those of the control group(2.54±0.58)points and(17.65±3.48)points,the 6-min walking test(6MWT)was(311.71±48.50)m,and the short-form health survey(SF-36)score was(78.34±9.35)points,which were higher than(279.34±44.72)m,(71.15±12.24)points in the control group,and the differences were statistically significant(P<0.05).The safety of the two groups was satisfactory,and no obvious adverse reactions were observed.Conclusion Feilike mixture combined with western medicine in the treatment of AECOPD patients can promote the outcome of patients,accelerate the relief of symptoms,signi
作者
黄容
肖嘉
HUANG Rong;XIAO Jia(Yichun Hospital of Traditional Chinese Medicine,Yichun Jiangxi 336000,China)
出处
《药品评价》
CAS
2023年第2期183-186,共4页
Drug Evaluation
关键词
肺疾病
慢性阻塞性
肺力咳合剂
血清学指标
运动耐量
倍氯米松
Pulmonary disease,chronic obstructive
Feilike mixture
Serological indexes
Exercise tolerance
Beclomethasone
